Perry, A., Wheeler-Martin, K., Hasin, D. S., Terlizzi, K., Mannes, Z. L., Jent, V., Townsend, T. N., Pamplin, J. R., Crystal, S., Martins, S. S., Cerdá, M., & Krawczyk, N. (2023). Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic. Drug and Alcohol Dependence, 253, 111023. https://doi.org/10.1016/j.drugalcdep.2023.111023

Ware, O. D., Ellis, J. D., Strain, E. C., Antoine, D. G., Martinez, S., & Bergeria, C. L. (2023). Increases in primary opioid use disorder diagnoses co-occurring with anxiety or depressive disorder diagnoses in mental health treatment in the United States, 2015–2019. Drug and Alcohol Dependence, 253, 111022. https://doi.org/10.1016/j.drugalcdep.2023.111022

Mariani, J. J., Dobbins, R. L., Heath, A., Gray, F., & Hassman, H. (2023). Open‐label investigation of rapid initiation of extended‐release buprenorphine in patients using fentanyl and fentanyl analogs. The American Journal on Addictions, 33(1), 8–14. Portico. https://doi.org/10.1111/ajad.13484

Shulman, M., Choo, T.-H., Scodes, J., Pavlicova, M., Novo, P., Campbell, A. N. C., Greiner, M., Lee, J. D., Rotrosen, J., & Nunes, E. V. (2023). Secondary Analysis of Agreement Between Negative Timeline Follow Back Report and Negative Urine Toxicology in a Large Trial of Individuals with Opioid Use Disorder. Journal of Addiction Medicine, 17(5), 618–620. https://doi.org/10.1097/adm.0000000000001173

Seval, N., Nunez, J., Roth, P., Schade, M., Strong, M., Frank, C. A., Litwin, A. H., Levin, F. R., Brady, K. T., Nunes, E. V., & Springer, S. A. (2023). Inpatient Low-dose Transitions From Full Agonist Opioids Including Methadone Onto Long-acting Depot Buprenorphine: Case Series From a Multicenter Clinical Trial. Journal of Addiction Medicine, 17(4), e232–e239. https://doi.org/10.1097/adm.0000000000001136

Justen, M., Scodes, J., Pavlicova, M., Choo, T.-H., Gopaldas, M., Haeny, A., Opara, O., Rhee, T. G., Rotrosen, J., Nunes, E. V., Hawk, K., & Edelman, E. J. (2023). Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT. Journal of Addiction Medicine, 17(4), 463–467. https://doi.org/10.1097/adm.0000000000001125

Tofighi, B., Badiei, B., Badolato, R., Lewis, C. F., Nunes, E., Thomas, A., & Lee, J. D. (2023). Integrating Text Messaging in a Low Threshold Telebuprenorphine Program for New York City Residents with Opioid Use Disorder during COVID-19: A Pilot Randomized Controlled Trial. Journal of Addiction Medicine, 17(5), e281–e286. https://doi.org/10.1097/adm.0000000000001161

Shiue, K. Y., Austin, A. E., Naumann, R. B., Aiello, A. E., Marshall, S. W., & Golightly, Y. M. (2023). Age, period and cohort-related trends in prescription opioid use in the USA, 1999–2018. Journal of Epidemiology and Community Health, 77(11), 714–720. https://doi.org/10.1136/jech-2023-220701

Paschen‐Wolff, M., Greenfield, S. F., Kathryn McHugh, R., Burlew, K., Pavlicova, M., Choo, T., Barbosa‐Leiker, C., Ruglass, L. M., Mennenga, S., Rotrosen, J., Nunes, E. V., & Campbell, A. N. C. (2023). Clinical and psychosocial outcomes by sex among individuals prescribed buprenorphine‐naloxone (BUP‐NX) or extended‐release naltrexone (XR‐NTX) for opioid use disorder. The American Journal on Addictions, 32(6), 584–592. Portico. https://doi.org/10.1111/ajad.13463

Shulman, M., Greiner, M., & Bisaga, A. (2023). Commentary on Foot et al.: Clinical considerations in addressing comorbid stimulant use in opioid use disorder. Addiction, 119(1), 158–159. Portico. https://doi.org/10.1111/add.16374

Gorfinkel, L., Stohl, M., Shmulewitz, D., & Hasin, D. (2023). Self-reported substance use with clinician interviewers versus self-administered surveys. Journal of Studies on Alcohol and Drugs. https://doi.org/10.15288/jsad.23-00004

Williams, A. R., Mauro, C. M., Feng, T., Waples, J., Martins, S. S., & Haney, M. (2023). Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance Use. Cannabis and Cannabinoid Research, 8(5), 933–941. https://doi.org/10.1089/can.2021.0212

Tardelli, V., Xu, K. Y., Bisaga, A., Levin, F. R., Fidalgo, T. M., & Grucza, R. A. (2023). Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk. BMJ Mental Health, 26(1), e300728. https://doi.org/10.1136/bmjment-2023-300728

Samples, H., Nowels, M. A., Williams, A. R., Olfson, M., & Crystal, S. (2023). Buprenorphine After Nonfatal Opioid Overdose: Reduced Mortality Risk in Medicare Disability Beneficiaries. American Journal of Preventive Medicine, 65(1), 19–29. https://doi.org/10.1016/j.amepre.2023.01.037

Williams, A. R., Mauro, C. M., Feng, T., Wilson, A., Cruz, A., Olfson, M., Crystal, S., Samples, H., & Chiodo, L. (2023). Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention. American Journal of Psychiatry, 180(6), 454–457. https://doi.org/10.1176/appi.ajp.20220456

Choe, K., Zinn, E., Lu, K., Hoang, D., & Yang, L. H. (2023). Impact of COVID-19 pandemic on chronic pain and opioid use in marginalized populations: A scoping review. Frontiers in Public Health, 11. https://doi.org/10.3389/fpubh.2023.1046683

Wilkerson, A. H., Sharma, M., Davis, R. E., Stephens, P. M., Kim, R. W., Bhati, D., & Nahar, V. K. (2023). Predisposing, enabling and reinforcing factors associated with opioid addiction helping behaviour in tri-state Appalachian counties: application of the PRECEDE–PROCEED model–cross-sectional analysis. BMJ Open, 13(5), e066147. https://doi.org/10.1136/bmjopen-2022-066147

Brandt, L., Hu, M.-C., Liu, Y., Castillo, F., Odom, G. J., Balise, R. R., Feaster, D. J., Nunes, E. V., & Luo, S. X. (2023). Risk of Experiencing an Overdose Event for Patients Undergoing Treatment With Medication for Opioid Use Disorder. American Journal of Psychiatry, 180(5), 386–394. https://doi.org/10.1176/appi.ajp.20220312

Landau, R., Cavanaugh, P. F., & DiGiorgi, M. (2023). Persistent opioid use after cesarean delivery in the United States of America: a systematic review. International Journal of Obstetric Anesthesia, 54, 103644. https://doi.org/10.1016/j.ijoa.2023.103644

Krawczyk, N., Rivera, B. D., Basaraba, C., Corbeil, T., Allen, B., Schultebraucks, K., Henry, B. F., Pincus, H. A., Levin, F. R., & Martinez, D. (2023). COVID‐19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems. Addiction, 118(5), 857–869. Portico. https://doi.org/10.1111/add.16105

Greiner, M. G., Shulman, M., Opara, O., Potter, K., Voronca, D. C., Tafessu, H. M., Hefner, K., Hamilton, A., Scheele, C., Ho, R., Dresser, L., Jelstrom, E., Fishman, M., Ghitza, U. E., Rotrosen, J., Nunes, E. V., & Bisaga, A. (2023). Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study. Contemporary Clinical Trials, 128, 107148. https://doi.org/10.1016/j.cct.2023.107148

Mahlstedt, J. H., Avery, J. D., & Mroczkowski, M. M. (2023). An Approach to Address the Need for Adolescent Opioid Stabilization and Treatment. The Primary Care Companion For CNS Disorders, 25(2). https://doi.org/10.4088/pcc.22br03441

Suri, A., Feaster, D. J., Balise, R. R., Quinn, J., Nunes, E. V., Gilbert, L., El‐Bassel, N., & Rundle, A. G. (2022). Impacts of the New York State COVID‐19 disaster emergency orders on prescription dispensing for opioids and medication for opioid use disorder. Addiction, 118(4), 711–718. Portico. https://doi.org/10.1111/add.16087

Daniulaityte, R., Nahhas, R. W., Silverstein, S., Martins, S., & Carlson, R. G. (2023). Trajectories of non–prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis. Journal of Substance Use and Addiction Treatment, 147, 208973. https://doi.org/10.1016/j.josat.2023.208973

Turi, E. R., McMenamin, A., Wolk, C. B., & Poghosyan, L. (2023). Primary care provider confidence in addressing opioid use disorder: A concept analysis. Research in Nursing & Health, 46(2), 263–273. Portico. https://doi.org/10.1002/nur.22294

West, B. S., Diaz, J. E., Philbin, M. M., & Mauro, P. M. (2023). Past-year medical and non-medical opioid use by HIV status in a nationally representative US sample: Implications for HIV and substance use service integration. Journal of Substance Use and Addiction Treatment, 147, 208976. https://doi.org/10.1016/j.josat.2023.208976

Gutkind, S., Askari, M. S., Perlmutter, A. S., Nesoff, E. D., Mauro, P. M., & Martins, S. S. (2023). Associations between relative deprivation with opioid use among working-age adults during the great recession. Journal of Psychiatric Research, 160, 101–109. https://doi.org/10.1016/j.jpsychires.2023.02.010

Luba, R., Jones, J., Choi, C. J., & Comer, S. (2022). Fentanyl withdrawal: Understanding symptom severity and exploring the role of body mass index on withdrawal symptoms and clearance. Addiction, 118(4), 719–726. Portico. https://doi.org/10.1111/add.16100

CERDÁ, M., KRAWCZYK, N., & KEYES, K. (2023). The Future of the United States Overdose Crisis: Challenges and Opportunities. The Milbank Quarterly, 101(S1), 478–506. Portico. https://doi.org/10.1111/1468-0009.12602

Chandler, R., Nunes, E. V., Tan, S., Freeman, P. R., Walley, A. Y., Lofwall, M., Oga, E., Glasgow, L., Brown, J. L., Fanucchi, L., Beers, D., Hunt, T., Bowers-Sword, R., Roeber, C., Baker, T., & Winhusen, T. J. (2023). Community selected strategies to reduce opioid-related overdose deaths in the HEALing (Helping to End Addiction Long-term SM) communities study. Drug and Alcohol Dependence, 245, 109804. https://doi.org/10.1016/j.drugalcdep.2023.109804

Williams, A. R., Aronowitz, S. V., Rowe, C., Gallagher, R., Behar, E., & Bisaga, A. (2023). Telehealth for opioid use disorder: retention as a function of demographics and rurality. The American Journal of Drug and Alcohol Abuse, 49(2), 260–265. https://doi.org/10.1080/00952990.2023.2180382

Hirchak, K. A., Nadeau, M., Vasquez, A., Hernandez‐Vallant, A., Smith, K., Pham, C., Oliver, K. A., Baukol, P., Lizzy, K., Shaffer, R., Herron, J., Campbell, A. N. C., & Venner, K. L. (2022). Centering culture in the treatment of opioid use disorder with American Indian and Alaska Native Communities: Contributions from a National Collaborative Board. American Journal of Community Psychology, 71(1–2), 174–183. Portico. https://doi.org/10.1002/ajcp.12620

Ruglass, L. M., Shevorykin, A., Zhao, Y., Killeen, T. K., Bauer, A. G., Morgan-López, A. A., Back, S. E., Fitzpatrick, S., López-Castro, T., Norman, S. B., Saavedra, L. M., & Hien, D. A. (2023). Self-report and urine drug screen concordance among women with co-occurring PTSD and substance use disorders participating in a clinical trial: Impact of drug type and participant characteristics. Drug and Alcohol Dependence, 244, 109769. https://doi.org/10.1016/j.drugalcdep.2023.109769

Williams, A. R., Aronowitz, S., Gallagher, R., Behar, E., Gray, Z., & Bisaga, A. (2022). A Virtual-First Telehealth Treatment Model for Opioid Use Disorder. Journal of General Internal Medicine, 38(3), 814–816. https://doi.org/10.1007/s11606-022-07955-x

Nguyen, R. H. N., Knapp, E. A., Li, X., Camargo, C. A., Conradt, E., Cowell, W., Derefinko, K. J., Elliott, A. J., Friedman, A. M., Khurana Hershey, G. K., Hofheimer, J. A., Lester, B. M., McEvoy, C. T., Neiderhiser, J. M., Oken, E., Ondersma, S. J., Sathyanarayana, S., Stabler, M. E., … Stroustrup, A. (2023). Characteristics of Individuals in the United States Who Used Opioids During Pregnancy. Journal of Women’s Health, 32(2), 161–170. https://doi.org/10.1089/jwh.2022.0118

Castillo, F., Scalise, D., Hernandez, D., Gupta, R., Basaraba, C. N., Corbeil, T., Comer, S. D., & Schneeberger, A. R. (2022). Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City. Journal of Addictive Diseases, 41(1), 91–97. https://doi.org/10.1080/10550887.2022.2067463

Jones, J. D., Rajachandran, L., Yocca, F., Risinger, R., De Vivo, M., Sabados, J., Levin, F. R., & Comer, S. D. (2023). Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial. The American Journal of Drug and Alcohol Abuse, 49(1), 109–122. https://doi.org/10.1080/00952990.2022.2144743

Lee, J. J., Saraiya, N., & Kuzniewicz, M. W. (2022). Prenatal Opioid Exposure and Neurodevelopmental Outcomes. Journal of Neurosurgical Anesthesiology, 35(1), 142–146. https://doi.org/10.1097/ana.0000000000000876

Kiluk, B. D., Kleykamp, B. A., Comer, S. D., Griffiths, R. R., Huhn, A. S., Johnson, M. W., Kampman, K. M., Pravetoni, M., Preston, K. L., Vandrey, R., Bergeria, C. L., Bogenschutz, M. P., Brown, R. T., Dunn, K. E., Dworkin, R. H., Finan, P. H., Hendricks, P. S., Houtsmuller, E. J., Kosten, T. R., … Strain, E. C. (2023). Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder. JAMA Psychiatry, 80(1), 84. https://doi.org/10.1001/jamapsychiatry.2022.4020

Luba, R., Martinez, S., Jones, J., Pravetoni, M., & Comer, S. D. (2023). Immunotherapeutic strategies for treating opioid use disorder and overdose. Expert Opinion on Investigational Drugs, 32(1), 77–87. https://doi.org/10.1080/13543784.2023.2173062

Paschen-Wolff, M. M., Kidd, J. D., & Paine, E. A. (2023). The State of the Research on Opioid Outcomes Among Lesbian, Gay, Bisexual, Transgender, Queer, and Other Sexuality- and Gender-Diverse Populations: A Scoping Review. LGBT Health, 10(1), 1–17. https://doi.org/10.1089/lgbt.2022.0036

Logue, T. C., Wen, T., & Friedman, A. M. (2022). Demographic trends associated with substance use disorder and risk for adverse obstetric outcomes with cannabis and opioid use disorders. The Journal of Maternal-Fetal & Neonatal Medicine, 35(26). https://doi.org/10.1080/14767058.2022.2128658

Bunting, A. M., Krawczyk, N., Choo, T.-H., Pavlicova, M., McNeely, J., Tofighi, B., Rotrosen, J., Nunes, E., & Lee, J. D. (2022). Polysubstance use before and during treatment with medication for opioid use disorder: Prevalence and association with treatment outcomes. Journal of Substance Abuse Treatment, 143, 108830. https://doi.org/10.1016/j.jsat.2022.108830

Williams, A. R., Johnson, K. A., Thomas, C. P., Reif, S., Socías, M. E., Henry, B. F., Neighbors, C., Gordon, A. J., Horgan, C., Nosyk, B., Drexler, K., Krawczyk, N., Gonsalves, G. S., Hadland, S. E., Stein, B. D., Fishman, M., Kelley, A. T., Pincus, H. A., & Olfson, M. (2022). Commentary Article: Opioid use Disorder Cascade of Care Framework Design: A Roadmap. Substance Abuse, 43(1), 1207–1214. https://doi.org/10.1080/08897077.2022.2074604

Joiner, E. F., Neira, J. A., Yevudza, W. E., Weller, M. A., Wagener, G., Angevine, P. D., & Mandigo, C. E. (2022). Surgeon-Delivered Nerve Block for Reduction of Perioperative Pain and Opioid Use After Lumbosacral Spine Surgery. JAMA Network Open, 5(12), e2248439. https://doi.org/10.1001/jamanetworkopen.2022.48439

Hirchak, K. A., Amiri, S., Kordas, G., Oluwoye, O., Lyons, A. J., Bajet, K., Hahn, J. A., McDonell, M. G., Campbell, A. N. C., & Venner, K. (2022). Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes. Substance Abuse Treatment, Prevention, and Policy, 17(1). https://doi.org/10.1186/s13011-022-00457-3

Maricich, Y. A., Nunes, E. V., Campbell, A. N. C., Botbyl, J. D., & Luderer, H. F. (2022). Safety and Efficacy of a Digital Therapeutic for Substance use Disorder: Secondary Analysis of Data from a NIDA Clinical Trials Network Study. Substance Abuse, 43(1), 937–942. https://doi.org/10.1080/08897077.2022.2060425

Krawczyk, N., Rivera, B. D., Jent, V., Keyes, K. M., Jones, C. M., & Cerdá, M. (2022). Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019”. International Journal of Drug Policy, 110, 103786. https://doi.org/10.1016/j.drugpo.2022.103786

Petrakis, I., Springer, S. A., Davis, C., Ralevski, E., Gu, L., Lew, R., Hermos, J., Nuite, M., Gordon, A. J., Kosten, T. R., Nunes, E. V., Rosenheck, R., Saxon, A. J., Swift, R., Goldberg, A., Ringer, R., & Ferguson, R. (2022). Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addiction Science & Clinical Practice, 17(1). https://doi.org/10.1186/s13722-022-00286-6

Castillo, F., Jones, J. D., Luba, R. R., Mogali, S., Foltin, R. W., Evans, S. M., & Comer, S. D. (2022). Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Pharmacology Biochemistry and Behavior, 221, 173482. https://doi.org/10.1016/j.pbb.2022.173482